CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 149 enrolled
Drug / intervention
bb2121biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03361748
NCT03361748Phase 2Completed
CompareCT.gov

A Phase 2, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma

Celgene·interventional·Posted Dec 5, 2017·Updated May 23, 2025

In Brief

A Phase 2 clinical trial evaluating bb2121 for Multiple Myeloma. Completed, enrolled 149 participants across 48 sites in 8 countries.

Detailed Summary

This is an open label, single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma. A leukapheresis procedure will be performed to manufacture bb2121 chimeric antigen receptor (CAR) modified T cells. Prior to bb2121 infusion subjects will receive lymphodepleting therapy with fludarabine and cyclophosphamide.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesBelgium, Canada, France, Germany, Italy, Japan, Spain, United States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedDec 5, 2017
Enrollment StartDec 13, 2017
Primary CompletionDec 20, 2023
TodayJul 2, 2026
Enrollment to primary: 6.0 yearsPosted 8.6 years ago

Interventions

bb2121biological

: bb2121 consists of autologous T lymphocytes transduced with an anti-BCMA02 CAR lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).